NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aruna Bio, Inc.

Aruna Bio, Inc.

Private
Athens, GeorgiaHealthcare & Life Scienceshttps://www.arunabio.com/

Last Round

Grant

Jun 1, 2022

Total Funding Raised

$10.15M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Aruna Bio, Inc. is a biotechnology company that develops a neural exosome platform to prepare medicine for the treatment of neural diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

exosome therapeuticsneural exosome platformblood-brain barrierBBB drug deliveryCNS drug deliverydrug delivery vehiclebiologic drug deliveryneurodegeneration treatmentAB126exosome manufacturingcGMP manufacturingpayload deliveryacute ischemic strokeallogeneic therapeuticamyotrophic lateral sclerosisALSRNA delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aruna Bio, Inc. Comparables

Compare Aruna Bio, Inc. with similar companies based on industry and business-model similarity.

Aruna Bio, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VivaZome Therapeutics
82%
ReNeuron Group
80%
Florica Therapeutics
79%

Aruna Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 1, 2022
VC RoundApr 14, 2021
GrantSep 12, 2019
VC RoundJul 24, 2019
AngelSep 27, 2018

Key People

Founding team and executive leadership

Steven Stice

Co-Founder Chief Scientific Officer

Founding Team

Tracey Worthington Stice

Chief Operating Officer

Executive Team

Aruna Bio, Inc. Investors

Notable investors and investment history

Aruna Bio, Inc. investors
InvestorRounds
Eshelman VenturesVC Round
National Institute of Neurological Disorders and StrokeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 39, 134% of headcount.

  • Jan 8, 2026

    Monthly visitors increased 149% MoM.

Aruna Bio, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aruna Bio, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aruna Bio, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersAthens, Georgia
Employee Range29
Year Founded2003
Last FundingJun 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.